Owing to the high morbidity of cardiovascular diseases (CVD) in patients with chronic kidney disease (CKD), renal biomarkers such as beta-2-microglobulin (B2M), cystatin C and lipocalin-2 (LCN-2) have attracted increasing attention. This evidence concerns the gene B2M and chronic kidney disease.